Reimbursement Approval of Evrysdi® for the Treatment of Spinal Muscular Atrophy

On 1 September the HSE announced that Risdiplam (Evrysdi®) has been approved for reimbursement in Ireland. This makes Risdiplam the third SMA medicine available in Ireland, alongside Zolgensma and Spinraza.